Ascentage pharma announces partial exercise of underwriters' option to purchase additional american depositary shares

Rockville, md. and suzhou, china, feb. 07, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg, hkex: 6855) announced today that the underwriters of its underwritten u.s. initial public offering (the “offering”) have partially exercised their over-allotment option to purchase an additional 935,144 american depositary shares (“adss”) at the initial public offering price of $17.25 per ads less underwriting discounts and commissions. each ads represents four ordinary shares of ascentage pharma. after giving effect to the partial exercise of the over-allotment option, the total number of adss sold by ascentage pharma in the offering will increase to 8,260,144 adss and the aggregate gross proceeds to ascentage pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by ascentage pharma. the closing of the over-allotment option is subject to customary closing conditions.
AAPG Ratings Summary
AAPG Quant Ranking